MEDVi is one of the largest compounded GLP-1 telehealth platforms in the US, with 100,000+ patients served, a 4.4/5 Trustpilot rating, and the only platform offering both injectable AND oral semaglutide and tirzepatide. Pricing starts at $179 for the first month, with coverage in 49 states. If you want a budget-friendly path to compounded GLP-1 medication from licensed US providers with reliable shipping, MEDVi is one of the strongest options in 2026. Here is the full breakdown of pricing, treatment options, and real patient results.
🔑 Why MEDVi Stands Out
- Best in category for treatment flexibility: MEDVi is the ONLY compounded GLP-1 telehealth platform offering both injectable AND oral tablet forms of semaglutide and tirzepatide. If needles are a barrier, this is your option.
- Lowest first-month entry in the space: Start compounded semaglutide for $179 for your first month, dramatically lower than retail Wegovy ($1,000+/month).
- Massive coverage and scale: Operates in 49 US states (all except Mississippi), with 100,000+ patients served. Dispensed by FDA-registered, cGMP-compliant US compounding pharmacies, prescribed by licensed US physicians.
- Reliable shipping that arrives on time: Patients consistently report medication arriving within the promised window.
- Strong patient ratings: 4.4/5 on Trustpilot, 4.7/5 self-reported across 100,000+ users. Positive reviewers consistently praise the empathetic care team and the nurse follow-up calls.
- Flexible payment: Pay with credit card or use Klarna, Afterpay, or Affirm to split costs into smaller installments.
- Money-back guarantee available (read exact terms at checkout).
Affiliate disclosure: PeptideDeck has an affiliate relationship with MEDVi. If you sign up through our links, we may earn a commission at no cost to you. We disclose this so you can weight our review accordingly. Our analysis below includes both the documented FDA warning letter and the ConsumerAffairs rating (3.6/5) that some affiliate reviews omit. This is a deliberately balanced take.
What Is MEDVi?
MEDVi (medvi.com) is a US-based telehealth platform that connects patients with licensed US physicians and 503A compounding pharmacies for personalized weight management treatment. The defining strength is the breadth of medication options: MEDVi offers compounded semaglutide and tirzepatide in BOTH injectable AND oral tablet forms, which is rare in the category.
The platform launched with a focus on accessible cash-pay GLP-1 weight management at a fraction of branded retail cost. As of mid-2026 it claims to have served more than 100,000 patients, making it one of the highest-volume operators in the space. New York Times coverage in early 2026 valued the parent company at $1.8 billion, signaling significant operational scale.
Key operational details:
- Coverage: 49 US states. Mississippi excluded due to state telehealth regulations.
- Pharmacies: FDA-registered, cGMP-compliant US compounding pharmacies (MEDVi does not compound medications itself).
- Providers: Licensed US physicians who review intake forms asynchronously.
- Medication forms: Injectable (weekly subcutaneous) and oral tablets for both semaglutide and tirzepatide.
- Money-back guarantee: MEDVi advertises a money-back guarantee window. Read the exact terms in your intake — some reviewers reported the window shifted from 3 months to 5 months at certain points in 2025-2026.
How MEDVi Works: The 5-Step Process
| Step | What happens | Time |
|---|---|---|
| 1. Medical history intake | Online questionnaire: health history, current medications, allergies, BMI, weight goals. | 5-10 min |
| 2. Provider review | Licensed US physician reviews your intake. Asynchronous, no live video. | up to 24-48 hr |
| 3. Personalized plan | Provider determines whether GLP-1 is appropriate and selects starting dose / formulation (injectable vs oral). | Same as review |
| 4. Receive medication | Prescription filled by partner 503A compounding pharmacy. Shipped to your door. | 3-7 days |
| 5. Begin treatment + follow-ups | Self-administer weekly (or per protocol). Portal access for provider messages, dose adjustments, refills. | Ongoing |
Total time from signup to first dose: typically 4 to 9 days. Slightly slower than the fastest competitors (Yucca averages 4-7), but within normal range for the category.
MEDVi Pricing in 2026
MEDVi's pricing is structured with a promotional first month and a higher ongoing refill rate. Know both numbers before signing up.
| Treatment | First month | Ongoing monthly refill | Notes |
|---|---|---|---|
| Compounded Semaglutide (injectable) | $179 | $299 | Weekly subcutaneous |
| Compounded Tirzepatide (injectable) | $258 typical entry | $299-399 depending on dose | Weekly subcutaneous |
| Oral Semaglutide / Tirzepatide tablets | Variable; check intake | Variable | Daily sublingual / oral; lower bioavailability than injectable |
Things to confirm in your intake (per ConsumerAffairs review patterns):
- Auto-renewal terms: when does the first-month rate end and the $299 ongoing rate begin?
- Money-back guarantee window: the public site advertises this but the exact window length has shifted; confirm in writing at checkout
- Cancellation policy: how do you cancel, what's required, and what happens to your remaining shipments?
- Dose-escalation pricing: as your provider raises your dose, what happens to the monthly cost?
For a broader pricing comparison vs other compounded GLP-1 platforms, see our GLP-1 cost without insurance guide and the cheapest tirzepatide guide.
Treatment Options: Injectable + Oral
MEDVi's strongest competitive differentiation in 2026 is the breadth of medication formats it offers. Most competitors offer only injectable semaglutide and tirzepatide. MEDVi offers both:
- Injectable compounded semaglutide and tirzepatide: The standard once-weekly subcutaneous injection format. Same active ingredients as Wegovy / Zepbound / Mounjaro. Higher bioavailability and the format with the most clinical data.
- Oral tablet semaglutide and tirzepatide: Daily oral or sublingual tablets. Lower bioavailability than injectable (a known pharmacological constraint of orally administered peptides). Useful for needle-averse patients but expect slightly less weight loss at the same nominal mg dose.
The oral tablet question deserves honesty: peptide absorption through the GI tract is challenging because of stomach acid and intestinal enzymes that degrade most peptides before they reach the bloodstream. The branded oral semaglutide that exists (Rybelsus, FDA-approved) uses a specific absorption enhancer (SNAC) and requires strict fasting protocols. Compounded oral tablets generally don't have the same scientifically validated absorption pathway, so real-world bioequivalence to injectable is a meaningful open question. We cover this in depth in our oral vs injectable semaglutide guide.
What Patient Reviews Actually Say
MEDVi cites a 4.7/5 rating from 100,000+ users on its own site. Independent review aggregators tell a more nuanced story.
| Source | Rating | Review count | Notes |
|---|---|---|---|
| MEDVi self-reported (on site) | 4.7/5 | 100,000+ | Aggregated from internal channels |
| ConsumerAffairs | 3.6/5 | ~1,600 | Heavier weight in negative reviews |
| Trustpilot (medvi.org) | 4.4/5 | Public reviews on medvi.org page | Higher than ConsumerAffairs; positive reviews dominate; critical reviews concentrate on billing/cancellation |
What positive reviewers consistently say:
- Appetite suppression that actually works. The most common positive theme is that hunger and cravings genuinely drop within the first 1-2 weeks, consistent with what GLP-1 should do.
- Measurable weight loss that tracks expectations. Reviewers commonly report 1-3 lbs/week in the first month, in line with branded GLP-1 trial averages.
- Fast shipping that arrives on time. Medication consistently arrives within the promised window.
- Accessible $179 first-month entry. The promotional first month makes GLP-1 affordable for patients who can't commit hundreds upfront.
- Easy online enrollment. The intake-to-prescription path is genuinely streamlined.
What critical reviewers consistently flag:
- Billing confusion around auto-renewal. The biggest complaint cluster on ConsumerAffairs. Patients report being unclear when the $179 promotional rate ended and the $299 monthly rate began, and being charged before they expected.
- Difficulty getting refunds. Several reviewers report friction with the refund process, especially mid-cycle.
- Money-back guarantee terms that shifted. Some reviewers mention the guarantee window appearing to change from 3 months to 5 months at different points, creating confusion.
- Customer service delays during peak growth. 2025-early 2026 saw rapid customer growth that strained support response times.
- Oral tablet results that underperformed expectations. Some reviewers report the oral format produced less weight loss than they hoped, consistent with the lower bioavailability issue described above.
The honest read: most negative reviews concern billing/refund disputes during MEDVi's rapid scale-up, not medication efficacy. The patients who lost weight kept losing weight; the platform's growing pains showed up in financial / customer-service touchpoints.
Real Trustpilot Reviews: What MEDVi Patients Actually Say
To balance the FDA enforcement context with real-world patient experience, here are actual MEDVi reviews pulled directly from Trustpilot (medvi.org page). MEDVi's current Trustpilot rating is 4.4/5 “Excellent”, which is meaningfully higher than the ConsumerAffairs 3.6/5 we cited earlier in this review (both ratings are real; reviewers self-select to each platform). We include both positive and critical reviews verbatim so you can decide.
Positive reviews (from May 2026)
“One thing that I like about this company is that all of the people I have communicated with have been individuals who are on their own weight-loss journeys. This makes them able to empathize with those of us struggling. They give off the impression of genuine concern. They’ve always responded promptly and I’ve always felt heard.”
“She listened to my concerns and questions and I was satisfied with what I need for success in the future.”
“Nurse Lorraine answered all my questions thoroughly and explained her concerns. Very pleasant!”
“Having staff available to follow up on the application and being able to talk about concerns is a great approach.”
“On time, very understandable nurse and answers questions well.”
“Thank you for being there. THANK YOU for listening. AND THANK YOU FOR THE WONDERFUL SUGGESTIONS TO MAKE THIS WORK!!!”
Critical reviews (for honest balance)
Not every review is glowing. The pattern in MEDVi's critical reviews concentrates on billing and cancellation friction, not medication issues. We include three verbatim:
“I ordered GLP-1 meds from Medvi and when I set up the account and mentioned I had recently had surgery they said I need a doctor’s release. I was charged the initial $149 on 4/22/26. Meanwhile Medvi charged me another $299.11 28 days later for another month’s medication. I asked for a refund and to cancel my account. The response: refund denied.”
“I used the chat to request cancellation. They told me they would submit it. Come May 14th I had a charge for $399.01. I contacted them again, they had no record of the cancellation chat. They told me chat records can’t be released to patients.”
“I signed up for a six month plan. I didn’t see the fine print where I would be charged in full up front. I was dismayed to see the $1,500 charge. Two months in I started feeling depressed and asked for a refund. They said they were sorry but would not refund. 5 months in, lost 5 pounds.”
The honest read of the Trustpilot data (4.4/5 across the public reviews shown):
- The positive reviews concentrate on nurse / care-team communication quality and the empathetic tone of customer support. Multiple reviewers specifically praise the staff and the listening approach.
- The critical reviews concentrate almost entirely on auto-renewal billing surprises and difficulty cancelling mid-cycle. None of the critical reviews we found alleged the medication itself was dangerous or ineffective on its own merits.
- The pattern matches ConsumerAffairs: medication does what GLP-1 is supposed to do; the friction is in the billing/cancellation touchpoints.
- MEDVi responds to negative reviews on Trustpilot publicly, which is a positive operational signal in itself — some competitors don't respond at all.
Compounded vs Branded: What This Means for MEDVi
MEDVi's medications are compounded, not FDA-approved branded drugs. The active pharmaceutical ingredient (semaglutide or tirzepatide) is the same molecule found in Wegovy / Ozempic and Zepbound / Mounjaro respectively. The regulatory difference matters:
| Aspect | Branded (Wegovy, Zepbound) | Compounded (MEDVi) |
|---|---|---|
| FDA-approved as finished drug? | Yes | No |
| Manufacturer | Novo Nordisk / Eli Lilly under FDA inspection | State-licensed 503A compounding pharmacies under State Board of Pharmacy oversight |
| Active ingredient | Same molecule | Same molecule |
| Typical cost | $900-$1,350/mo retail without insurance | $179-$299/mo at MEDVi |
| Insurance coverage | Sometimes covered for eligible diagnoses | Almost never covered |
| FDA marketing oversight | Strict; subject to FDA-DTC ad rules | Subject to FDA misbranding rules per the Feb 2026 enforcement wave |
For the full picture on compounded GLP-1 regulation, see compounded semaglutide guide.
Who Qualifies for MEDVi
Eligibility is determined by a licensed US provider based on intake form review. Standard medical-weight-management criteria apply:
- BMI of 30 or above (standard obesity classification), or
- BMI of 27 or above with at least one weight-related comorbidity (type 2 diabetes, hypertension, hyperlipidemia)
You will not be approved if you have:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Active pancreatitis
- Active pregnancy or breastfeeding
- Severe gastroparesis or recent bowel obstruction
Mississippi residents cannot use MEDVi due to state telehealth regulations.
Pros and Cons (Honest)
✅ Pros
- Lowest first-month entry in the category at $179 for semaglutide
- Both injectable AND oral GLP-1 available — rare in the space
- 49-state coverage (only excludes Mississippi)
- FDA-registered, cGMP-compliant 503A compounding pharmacies
- Money-back guarantee offered (read exact terms before signup)
- Significant scale — 100,000+ patients served implies operational maturity
- Easy online enrollment; consistent positive feedback on this
- Reliable shipping; arrives within promised window
- Affordable cash-pay path for patients without GLP-1 insurance coverage
⚠️ Cons
- February 2026 FDA warning letter for misbranding (industry-wide action, but real)
- ConsumerAffairs 3.6/5 vs self-reported 4.7/5 — independent rating is lower
- First-month rate ($179) jumps to $299 on refills — surprise for some patients
- Auto-renewal billing is the #1 negative theme in reviews; read terms carefully
- Money-back guarantee window has shifted historically; confirm at checkout
- Customer service strain during rapid 2025-2026 growth; better in some periods than others
- Oral tablet bioavailability is lower than injectable — same nominal dose, less weight loss
- Compounded medications are not FDA-approved (same caveat applies to every compounded GLP-1 telehealth)
- Insurance typically does not cover compounded GLP-1
- Not available in Mississippi
MEDVi vs Competitors: Head-to-Head
How does MEDVi compare to the rest of the compounded GLP-1 telehealth field?
| Provider | Sema starting | Tirz starting | Oral option? | FDA warning? | Independent rating |
|---|---|---|---|---|---|
| MEDVi | $179 1st mo / $299 | $258 | Yes | Yes (Feb 2026) | 3.6/5 (CA, 1,600) |
| Yucca Health | $146/mo (6-mo plan) | $258 | No | No | 4.6/5 (Trustpilot, 1,108) |
| Henry Meds | $297/mo all-in | $297/mo all-in | No | No* | 4.5/5 |
| Ro Body | $45 1st / $135+ | Variable | No | No* | 4.2/5 |
| Form Health | $99-$209 | $99-$209 | No | No* | 4.4/5 |
| Mochi Health | $99/mo | $258/mo | No | No* | 4.5/5 |
* The Feb-March 2026 FDA enforcement wave targeted 30+ telehealth companies for similar marketing-language violations. Not all warning letters became as public as MEDVi's, but the industry-wide regulatory pressure applied broadly. We list MEDVi's explicitly here for transparency.
Where MEDVi wins:
- The only provider in the set offering oral tablets for both semaglutide and tirzepatide
- Lowest first-month entry price at $179 for semaglutide
- 49-state coverage is the broadest in the category
Where competitors win:
- Yucca Health has the strongest independent review rating (4.6/5 Trustpilot, 1,108 reviews) and a real onboarding call. See our Yucca Health review.
- Henry Meds bundles everything at a flat $297/mo, simpler if you hate variable pricing.
- Form Health uses board-certified obesity specialists with live video.
- Mochi Health matches MEDVi's low-cost positioning but with higher independent ratings.
For the full 10-provider ranking with strengths-and-weaknesses per provider, see our best online GLP-1 program guide.
Who MEDVi Is NOT Good For
Honest cases where MEDVi is the wrong fit:
- You're in Mississippi. MEDVi doesn't operate there. Try Yucca or Mochi.
- You want maximum independent-rating reassurance. Yucca Health's 4.6/5 across 1,108 verified Trustpilot reviews is a stronger signal than MEDVi's 3.6/5 ConsumerAffairs rating.
- You have insurance coverage for Wegovy or Zepbound. Branded with insurance is usually cheaper than MEDVi's cash-pay route.
- You're bothered by FDA enforcement history. The February 2026 warning letter is part of the public record. If that's a hard no, look elsewhere.
- You can't self-administer the auto-renewal pricing logic. If you suspect you'll forget to track the $179-to-$299 transition, you'll likely be unhappy. Stick with flat-pricing platforms like Henry Meds.
- You only want injectable and are paying a premium for the "oral tablet" option you won't use. Then a cheaper injectable-only platform (Yucca, Mochi) is the better fit.
Frequently Asked Questions
Bottom Line: Is MEDVi Worth It in 2026?
For patients seeking affordable, accessible compounded GLP-1 treatment with maximum flexibility, MEDVi is one of the strongest options available in 2026. The $179 first-month entry is the lowest in the category. The combination of injectable AND oral semaglutide and tirzepatide is unique among major telehealth platforms. The 49-state coverage is the broadest available. And the 4.4/5 Trustpilot rating reflects what patients consistently say: the appetite suppression works, the medication arrives on time, and the care team genuinely listens.
The compounded GLP-1 category has matured significantly in 2026. MEDVi operates within the legitimate 503A compounding framework, dispenses from FDA-registered cGMP-compliant pharmacies, and uses licensed US physicians for every prescription. The medication you receive contains the same active pharmaceutical ingredients as Wegovy and Zepbound at a fraction of retail cost.
If you qualify (BMI 30+ or BMI 27+ with a weight-related comorbidity), MEDVi is a credible choice for starting a medically guided weight loss journey without paying retail pharmacy prices or fighting insurance prior authorizations.
Get started: The intake form takes 5-10 minutes. A licensed US provider reviews your case within 24-48 hours. If approved, medication ships from a 503A pharmacy and arrives in 3-7 days. Start your MEDVi intake here or read our Yucca Health review if you want to compare a second strong option.
Regulatory Context: The February 2026 FDA Industry-Wide Letter
For full transparency, here is the regulatory context most affiliate reviews omit. In early 2026, the FDA conducted an industry-wide enforcement sweep against 30+ compounded GLP-1 telehealth platforms for marketing-language violations. MEDVi received a warning letter on February 20, 2026 (MARCS-CMS 721455) as part of this broader wave, alongside many of its competitors. The violations were entirely about website language and product labeling, not about medication safety or efficacy. MEDVi adjusted the cited language in response.
What the FDA actually cited:
- Labeling issue: MEDVi's product pages displayed compounded semaglutide and tirzepatide vials with "MEDVi" on the pictured label, which the FDA said falsely suggested MEDVi itself was the compounder. (MEDVi is the telehealth platform; it does not operate its own compounding pharmacy. The medications are dispensed by partner 503A compounding pharmacies.)
- Implied FDA approval: Marketing copy like "Same active ingredient as Wegovy® and Ozempic®" and "Same active ingredient as Mounjaro® and Zepbound®" was cited as falsely implying that MEDVi's compounded products had been FDA-approved or evaluated for safety and effectiveness. Compounded drug products are not FDA-approved.
The important context:
- This was a marketing/labeling issue, not a safety or efficacy issue. The FDA did not allege the compounded medications themselves were dangerous or ineffective. The violation was about how MEDVi's website presented the products.
- It was part of a broader industry-wide FDA enforcement wave. The FDA issued similar warning letters to 30+ telehealth companies in early 2026 for substantially the same marketing-language violations. MEDVi was hit because of its size and visibility, but it was far from alone.
- The cited claims still appear on many compounded GLP-1 telehealth sites in similar form. The whole industry leaned heavily on "same active ingredient as Wegovy" language until the FDA started enforcing.
- The warning letter is publicly available on FDA.gov for anyone to read in full. We linked it in the references at the bottom.
What changed: MEDVi was given an opportunity to respond and adjust its website language. We checked the public site in May 2026 and the disclaimers around compounded medications are now more prominently displayed than they were when the FDA observed the violations in December 2025.
How to weight this in your decision: If FDA enforcement history is a dealbreaker, this matters. If you understand it was an industry-wide marketing-language enforcement (not a safety recall), it matters less. For context on the broader compounded GLP-1 regulatory picture, see our compounded semaglutide guide and tirzepatide compounding pharmacy guide.
📚 References & Sources
- FDA Warning Letter to MEDVi, LLC dba MEDVi - MARCS-CMS 721455, February 20, 2026. FDA.gov public warning letter
- FDA enforcement actions on compounded GLP-1 telehealth marketing (industry-wide letters, early 2026).
- ConsumerAffairs MEDVi reviews aggregator (~1,600 reviews, 3.6/5 average as of mid-2026).
- MEDVi public site disclosures, accessed May 2026.
- Davies M et al. "Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2)." Lancet. 2021. (Branded semaglutide comparator data)
- Jastreboff AM et al. "Tirzepatide once weekly for the treatment of obesity." N Engl J Med. 2022;387(3):205-216. (Branded tirzepatide comparator data)
